IOSP

Innospec is a quality, conservatively-financed specialty chemical company that is currently a fairly-priced asset rather than a bargain. The balance sheet is the standout: zero long-term and current debt, $293M cash, $1.33B equity and a 0.38x liabilities/equity ratio, giving management the flexibility for M&A, dividends and buybacks that the MD&A explicitly flags. At $80.71 the stock trades at 17.3x FY2025 diluted EPS and just 1.1x sales — reasonable for a no-debt compounder, but not cheap given the underlying trends.

The headline EPS jump (+228.9% to $4.67) is misleading and the single most important thing to see through: it is a base-effect recovery off a depressed FY2024 ($35.6M net income). Operationally the business went backwards — operating income fell 27.2% to $130M, gross profit fell 9.3%, revenue declined 3.7% to $1.78B (the third straight year below the $1.96B 2022 peak), and operating cash flow dropped 25% to $138M. ROE is a modest 8.8% and net margin only 6.6%. So the 'earnings tripled' optics mask a company whose core profitability is contracting.